Avadel Pharmaceuticals (AVDL) Other Non-Current Liabilities: 2009-2022
Historic Other Non-Current Liabilities for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Sep 2022 value amounting to $5.7 million.
- Avadel Pharmaceuticals' Other Non-Current Liabilities rose 43.21% to $5.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.7 million, marking a year-over-year increase of 43.21%. This contributed to the annual value of $3.9 million for FY2021, which is 7.00% down from last year.
- As of Q3 2022, Avadel Pharmaceuticals' Other Non-Current Liabilities stood at $5.7 million, which was up 0.19% from $5.7 million recorded in Q2 2022.
- Avadel Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $14.3 million for Q1 2018, and its period low was $3.8 million during Q1 2022.
- For the 3-year period, Avadel Pharmaceuticals' Other Non-Current Liabilities averaged around $4.7 million, with its median value being $4.2 million (2020).
- Per our database at Business Quant, Avadel Pharmaceuticals' Other Non-Current Liabilities soared by 159.69% in 2018 and then slumped by 64.66% in 2020.
- Avadel Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $14.0 million in 2018, then crashed by 36.63% to $8.9 million in 2019, then plummeted by 52.53% to $4.2 million in 2020, then declined by 7.00% to $3.9 million in 2021, then skyrocketed by 43.21% to $5.7 million in 2022.
- Its last three reported values are $5.7 million in Q3 2022, $5.7 million for Q2 2022, and $3.8 million during Q1 2022.